• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Pembrolizumab plus chemotherapy improves survival in patients with metastatic triple-negative breast cancer

byConstance Wu
December 15, 2020
in StudyGraphics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. First line treatment with pembrolizumab-chemotherapy showed significant improvement in progression-free survival compared to chemotherapy alone in patients with metastatic triple-negative breast cancer and a CPS of 10 or more.

2. There was no significant increase in adverse events or death with the addition of pembrolizumab to standard first-line chemotherapy.

 Evidence Rating Level: 1 (Excellent)

Study Rundown: Triple-negative breast cancer is challenging to treat due to the absence of targets for therapeutic intervention. Cytotoxic chemotherapy remains the standard treatment for most patients, but these tumours become rapidly resistant to chemotherapy. Pembrolizumab is an anti-PD-1 monoclonal antibody which has shown promising anti-tumour activity across many tumour types with an acceptable safety profile. This randomized controlled phase 3 clinical trial aimed to evaluate the efficacy and safety of pembrolizumab plus chemotherapy to chemotherapy alone in patients with previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. Results suggested that pembrolizumab-chemotherapy resulted in significant, clinically meaningful improvements in progression-free survival compared to chemotherapy alone in patients with CPS ≥10. The benefits on progression-free survival were consistent across pre-defined subgroups including type of chemotherapy and disease-free interval. Treatment related adverse event rates were similar between groups. A key strength of the current study comes from its inclusion of both taxanes and platinum-based chemotherapy regimens allowing for the assessment of pembrolizumab in combination with different chemotherapy agents. However, the subgroup analysis showing persistent benefit of pembrolizumab irrespective of chemotherapy partner was underpowered and, as such, the results of subgroup analysis should be interpreted with caution.

Click to read the study in The Lancet

Relevant Reading: Pembrolizumab for Early Triple-Negative Breast Cancer

In-Depth [randomized controlled trial]: This randomized, placebo-controlled, double-blind, phase 3 clinical trial done in 209 sites in 29 countries around the world included adults aged >18 years of age with untreated locally recurrent inoperable or metastatic triple-negative breast cancer. Participants were randomized to pembrolizumab (200 mg) every 3 weeks plus chemotherapy (one of nab-paclitaxel, paclitaxel, or gemcitabine plus carboplatin) or placebo plus chemotherapy. Randomization was stratified by type of chemotherapy, PD-L1 expression at baseline (combined positive score (CPS) ≥1 or <1), or previous treatment by the same class of chemotherapy in adjuvant or neoadjuvant setting. The primary efficacy endpoints of this study were progression-free survival and overall survival in the intention-to-treat and subgroup analysis.

RELATED REPORTS

Alternative Dose Regimens of Exemestane in Postmenopausal Women with Breast Cancer

Sotorasib superior to docetaxel for treatment of KRASG12C-positive non-small-cell lung cancer

Combination therapy with alisterib and fulvestrant may be clinically advantageous in the treatment of endocrine-resistant advanced breast cancer

A total of 847 patients (median age=53) were randomly assigned to treatment with 566 patients in the pembrolizumab-chemotherapy group and 281 patients the placebo-chemotherapy group. Overall, among patients with CPS ≥10, median progression-free survival was 9.7 months on pembrolizumab-chemotherapy compared to 5.6 months on placebo-chemotherapy (hazard ratio [HR] for progression or death 0.65, 95% CI 0.49 to 0.86; p=0.0012). In patients with CPS of 1 or more, median progression-free survival was 7.6 months in the pembrolizumab-chemotherapy group and 5.6 months in the placebo-chemotherapy group (HR 0.74, 95% CI 0.61 to 0.90; p=0.0014 [not significant]). Adverse events considered to be related to study treatment occurred in 96% of patients in the pembrolizumab-chemotherapy group compared to 95% in the placebo-chemotherapy group with anemia (49% vs. 46%), neutropenia (41% vs. 38%) and nausea (39% vs. 41%) being the most common side effects noted. Death occurred in <1% of the pembrolizumab-chemotherapy group compared to 0% in the placebo-chemotherapy group.

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Breast Cancerchemotherapypdl-1Pembrolizumabtriple negative breast cancer
Previous Post

Febuxostat is not associated with worse cardiovascular safety outcomes or all-cause mortality compared to allopurinol

Next Post

#VisualAbstract: Oxygenated hypothermic perfusion reduces post-kidney transplant complications

RelatedReports

Adjuvant radiation decreases local recurrence in low-risk breast cancer
Oncology

Alternative Dose Regimens of Exemestane in Postmenopausal Women with Breast Cancer

March 27, 2023
Macitentan better than placebo for preventing progression of pulmonary arterial hypertension [SERAPHIN Trial]
Chronic Disease

Sotorasib superior to docetaxel for treatment of KRASG12C-positive non-small-cell lung cancer

March 14, 2023
Preoperative bilateral breast imaging may reduce contralateral cancer recurrence
Chronic Disease

Combination therapy with alisterib and fulvestrant may be clinically advantageous in the treatment of endocrine-resistant advanced breast cancer

March 12, 2023
#VisualAbstract: Neoadjuvant–Adjuvant vs. Adjuvant-Only Pembrolizumab in Advanced Melanoma
StudyGraphics

#VisualAbstract: Neoadjuvant–Adjuvant vs. Adjuvant-Only Pembrolizumab in Advanced Melanoma

March 9, 2023
Next Post
#VisualAbstract: Drug-coated balloons are noninferior to drug-eluting stents for treatment of small vessel coronary artery disease

#VisualAbstract: Oxygenated hypothermic perfusion reduces post-kidney transplant complications

Thrombophilia-associated stillbirth risk appears limited to factor V Leiden

Association between low density lipoprotein and all cause and cause specific mortality in Denmark

#VisualAbstract: Trends in positive BRCA results among older women between 2008 to 2018

#VisualAbstract: Trends in positive BRCA results among older women between 2008 to 2018

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • SAR-CoV-2 infection during pregnancy may lead to adverse neurodevelopmental outcomes in male offspring
  • Hyperfractionated radiotherapy reduces complication rates compared to standard fractionation for locally advanced nasopharyngeal carcinoma
  • Lebrikizumab effective in treating moderate-to-severe atopic dermatitis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options